0001356576-24-000003.txt : 20240205 0001356576-24-000003.hdr.sgml : 20240205 20240205092151 ACCESSION NUMBER: 0001356576-24-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240205 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 24594272 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 8-K 1 supn-20240205.htm 8-K supn-20240205
false000135657600013565762024-02-052024-02-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): February 5, 2024
 
Supernus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)
Delaware
001-3551820-2590184
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
9715 Key West Ave
Rockville
MD
20850
(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number, including area code: (301) 838-2500
 
Not Applicable
(Former name or former address, if changed since last report.)

  Securities registered pursuant to Section 12(b) of the Exchange Act
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.001 par value per shareSUPNThe Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 8.01 Other Events.
On February 5, 2024, Supernus Pharmaceuticals, Inc. (“Supernus”) issued a press release announcing that the United States District Court for the District of New Jersey ruled that Torrent Pharmaceuticals Ltd. Torrent Group and its subsidiary, Torrent Pharma Inc., infringed three patents by submitting to the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) seeking permission to market a generic version of Trokendi XR® before the expiration of Supernus’ patents. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit
The following document is furnished as an Exhibit pursuant to Item 8.01 hereof:
2

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

 SUPERNUS PHARMACEUTICALS, INC.
  
DATED: February 5, 2024By:/s/ Timothy C. Dec
  Timothy C. Dec
  Senior Vice President and Chief Financial Officer

3
 EX-99.1 2 ex99102-05x2024.htm EX-99.1 Document

Exhibit 99.1
 image_0.jpg

Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent

ROCKVILLE, Md., February 5, 2024 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the United States District Court for the District of New Jersey ruled that Torrent Pharmaceuticals Ltd. and its subsidiary, Torrent Pharma Inc., infringed U.S. Patent Nos. 8,992,989; 9,549,940; and 9,622,983 by submitting to the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) seeking permission to market a generic version of Trokendi XR® before the expiration of Supernus’ patents.
“We are very pleased with the District Court’s ruling that Torrent infringed our Trokendi XR® patents and the reaffirmation of the validity of those patents,” stated Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “We are very serious about securing intellectual property (IP) protection for our innovative products and about vigorously enforcing such IP rights even if the product is at a later stage in its lifecycle.”
In addition to the three patents that were the subject of the District Court’s decision, Trokendi XR® is further protected by seven other patents. The Orange Book lists a total of ten patents as covering Trokendi XR.
About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase its net revenue; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; the Company’s ability to increase the number of prescriptions written for each of its products and


the products of its subsidiaries; the Company’s ability to increase its net revenue from its products and the products of its subsidiaries; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

CONTACTS:

Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591

or

INVESTOR CONTACT:

Peter Vozzo
ICR Westwicke
Office: (443) 213-0505
Email: peter.vozzo@westwicke.com

 EX-101.SCH 3 supn-20240205.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 supn-20240205_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity Filer Name Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 supn-20240205_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_0.jpg begin 644 image_0.jpg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�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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover Page
Feb. 05, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 05, 2024
Entity Registrant Name Supernus Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity Filer Name 001-35518
Entity Tax Identification Number 20-2590184
Entity Address, Address Line One 9715 Key West Ave
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 301
Local Phone Number 838-2500
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SUPN
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001356576
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +E*15@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "Y2D58.!?U4>\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O;:K@J'+B^+3!H(#Q;>0W+9@TX3DI-VW-XU;A^@'\#%W__SN M=W"=\ERY@,_!>0QD,-Y,MA\B5W[-CD2> T1U1"MCF1)#:NY=L)+2,QS 2_4A M#PA-5=V!19):DH096/B%R$2G%5+0X4H2YK8&*> MZ$]3W\$5,,,(@XW?!=0+,5?_Q.8.L'-RBF9)C>-8CJN<2SO4\+;=O.1U"S-$ MDH/"]"L:3B>/:W:9_+IZ>-P],=%435M435'=[NJ6-S5O[]]GUQ]^5V'KM-F; M?VQ\$10=_+H+\0502P,$% @ N4I%6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "Y2D58B7[Z]E$$ "/$ & 'AL+W=O:,-UPPGW3Q$G.PR_GV,^).]@H_696C%GRG@EIAM[*VOS:]TVR8ADU%RIG M$NXLE,ZHA:%>^B;7C*9E4";\* AZ?D:Y]$:#\MI4CP:JL()+-M7$%%E&]?:& M";49>J'W<>&9+U?67?!'@YPNV8S9K_E4P\BO5%*>,6FXDD2SQ= ;A]H$C8H(EUDE0.*S9A GAE(#CW[VH5_VF"SP\ M_U"_+U\>7F9.#9LH\V?Z'8Z25*F/(OV>R>[78] MDA3&JFP?# 09E[LC?=\GXC @/!(0[0.BDGOW0R7E+;5T--!J0[1[&M3<2?FJ M933 <>FJ,K,:[G*(LZ.)6C--IE" @6]!SUWUDWWLS2XV.A)[S^87)(C/2!1$ MW?^'^X!1L4052U3J=5"6O\=S8S54ZY\FHIU"MUG!3>%KD].$#3V8HX;I-?-& M/_T0]H)?$;Y.Q=?!U$>W*BE@0EKRLLT;TX6']\\_(1#="J)[&L24::Y2%D17IY">,\%K(MCJ<0E@B \[\1QV$=P^A5._Q2<%_I.'E*8@GP! M52F]]:G(YDPWT>&*47 >Q5=!V,=FWU6%=W4*WCA-8>F;LX\3\AF>(U]D8_)P MQ:O+,":?V):\,F/)>,T0RC"H'3?X+LZ)&\&$>U$;V6C"N-RS2M[67 @4[J = MA-\%5RV'J59K+I/F-H%K/MYB:'5W"%%S_P9MJHRE@OS%\Z-KM$4Q"OIQ@+'5 MG2'$O;VLX1@^BXZCX *=(,1 ZNX0XJ;^68%1@F\JF//'5V6+2+_3AW49H*FI M>T*(F_D+MP)FT(*$T<_S7\B,)86&;#5BX4H3E65@-C,+,_Z,_!A<@+F1G&JR MIJ)@!'H&,= PT(50-X<0-_ 735,NEV2VS>9*--+B K.OTR>,I&X"(6[A'QDC M=^_)BLHE.]H*6H2>QK/;\1\84]T)0MRX7P'(,DE<20JY;P.FD0D76D!;1PM6 MNW^(F_5,"9YPZVKV")ZE.6VN&J[2QA/5-A_AOCS5[#R!]# PS=U7(Y,I3-$O MBT7SHFS1:R6K/3["_?@;L@=C"B!K!<1E6P$/]@$G.?U=QO32U?,W4+ K-]ER M*AN=HT6P%:TV^@CWZ3$D+"V3=B_HLA$%%VA%J:T^PEUZGZ4)P&CP_ TUD_L'VTFW5'ZDKBR&"+4 MN+@$V]:[W>]N8%5>[CCG MRL+^M3Q=,0ISRST ]Q=*V8^!V\16_X,8_0=02P,$% @ N4I%6)^@&_"Q M @ X@P T !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!A ML(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'( MN2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)" MTV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z" MX6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89B MW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05T MK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X M=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NF MJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+ MN.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV M&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J! M1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% M @ N4I%6)>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8 M_1!2:5K5N %(MB6/:( M7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1 MH2)8%II%R=.B':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$ MNW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45 M%K"FHO409.B1P74&0ZRQB28)UD-N5G0&3K;V"%TH?653#@%%G=W4Q7/4 6_* MP>-HK(0* Y1OJA65UY**+2?=T>M,[Q\FCUI&Z]Q*N??P2K8<&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z M=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2 MO6H0DBBZ0=@S9)[NF:*'3^ M 5!+ P04 " "Y2D5899!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S M72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2 M%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-; M$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKB MRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_' MG2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'" M[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( +E*15@'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ MN4I%6#@7]5'O *P( !$ ( !KP &1O8U!R;W!S+V-O M&UL4$L! A0#% @ N4I%6)E&PO=V]R:W-H965T&UL4$L! A0#% @ N4I%6)^@&_"Q @ X@P T M ( !E0P 'AL+W-T>6QE&PO=V]R:V)O;VLN M>&UL4$L! A0#% @ N4I%6"0>FZ*M ^ $ !H ( ! MOA$ 'AL+U]R96QS+W=O9(9 0 SP, !, ( !HQ( %M#;VYT96YT7U1Y<&5S ;72YX;6Q02P4& D "0 ^ @ [1, end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.supernus.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports supn-20240205.htm supn-20240205.xsd supn-20240205_lab.xml supn-20240205_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "supn-20240205.htm": { "nsprefix": "supn", "nsuri": "http://www.supernus.com/20240205", "dts": { "inline": { "local": [ "supn-20240205.htm" ] }, "schema": { "local": [ "supn-20240205.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "supn-20240205_lab.xml" ] }, "presentationLink": { "local": [ "supn-20240205_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.supernus.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240205.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "supn-20240205.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Name", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001356576-24-000003-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001356576-24-000003-xbrl.zip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end XML 17 supn-20240205_htm.xml IDEA: XBRL DOCUMENT 0001356576 2024-02-05 2024-02-05 false 0001356576 8-K 2024-02-05 Supernus Pharmaceuticals, Inc. DE 001-35518 20-2590184 9715 Key West Ave Rockville MD 20850 301 838-2500 Common Stock, $0.001 par value per share SUPN NASDAQ false false false false false